GlaxoSmithKline Hides Knowledge that It’s Drug Increases Heart Risks

The Food and Drug Administration (FDA) resolved to hold a two-day hearing to inspect the reports filed regarding the side effects of GlaxoSmithKline's drug Avandia. The defective drug is thought to increase the chance of heart attacks. These allegations, if proven correct, would result in the drug being withdrawn from the market.

SmithKline Beecham, the owner of GlaxoSmithKline, had taken up some researches to find out whether his drug was much healthier on hearts than its competitor, Actos.


FDA To Review GlaxoSmithKline's Avandia

Drugs major GlaxoSmithKline's important Avandia diabetes treatment could be prohibited on both sides of the Atlantic, as controllers individually prepare to provide their judgments on its future.

GSK's one-time largest retailing drug will be assessed by the US Food and Drug Administration on Tuesday and Wednesday next week.

The subsequent week, in a meeting beginning on July 19, the European Medicines Agency (EMA) will assess the medicine's vending in Europe that can result in it being cancelled, suspended or limited - or come to a decision that its business is normal.


GSK’s Diabetes Drug May Lead to Heart Attacks

GlaxoSmithKline Plc has been allegedly withholding a study showing that its Avandia diabetes drug may cause heart attacks, according to two people having the knowledge of a lawsuit filed against the drug maker.

Dr. Rosemary Johann-Liang, the former U.S. Food and Drug Administration official, has claimed that a study in 2001 had discovered that Avandia posed an augmented heart-attack risk than adversary medicines.

Glaxo also hadn’t reverted to an e-mail from researchers who had concluded that Avandia reinforced the signs of heart ailments.


Glaxo’s Avandia Increases Heart Risks

An US Food and Drug Administration (FDA) reviewer who worked on the study said government scients had analysed Avandia, GlaxoSmithKline Plc’s controversial diabetes drug and found it to increase heart risks, including deaths compared to a rival pill.

Known for opposing now-withdrawn painkiller Vioxx, Dr. David Graham and other government staff reviewed data on Medicare health insurance programme for the elderly patients taking Avandia or competitor Actos (Takeda Pharmaceutical Co Ltd.)


GlaxoSmithKline: Benlysta Applied For US Sanction by Collaborator HGSI

On Thursday, GlaxoSmithKline Plc. said that collaborator Human Genome Sciences Inc. has filed for U. S. regulatory sanction for their jointly developed medicine Benlysta, probably the first new cure in ages for the hard-to-cure autoimmune sickness, lupus.

Benlysta, or belimumab, is not backed up or approved anywhere in the globe, but the U. K. drug manufacturer and its Rockville, Md.-based associate have pinned high expectations for the treatment.



Subscribe to RSS - GlaxoSmithKline